<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell J</journal-id><journal-id journal-id-type="iso-abbrev">Cell J</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>Cell Journal (Yakhteh)</journal-title></journal-title-group><issn pub-type="ppub">2228-5806</issn><issn pub-type="epub">2228-5814</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29105398</article-id><article-id pub-id-type="pmc">5672102</article-id><article-id pub-id-type="other">Cell-J-19-627</article-id><article-id pub-id-type="doi">10.22074/cellj.2018.4577</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Genetics</subject><subject>Gynecology and Female Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>Oral Quercetin Supplementation Enhances Adiponectin Receptor
Transcript Expression in Polycystic Ovary Syndrome Patients: A
Randomized Placebo-Controlled Double-Blind Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rezvan</surname><given-names>Neda</given-names></name><degrees>M.Sc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moini</surname><given-names>Ashraf</given-names></name><degrees>M.D</degrees><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gorgani-Firuzjaee</surname><given-names>Sattar</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hosseinzadeh-Attar</surname><given-names>Mohammad Javad</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1"><label>1</label>Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical
Sciences, Tehran, Iran</aff><aff id="A2"><label>2</label>Department of Obstetrics and Gynecology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran </aff><aff id="A3"><label>3</label>Department of Obstetrics and Gynecology, Arash Women&#x02019;s Hospital, Tehran University of Medical Sciences, Tehran, Iran </aff><aff id="A4"><label>4</label>Department of Medical Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran </aff></contrib-group><author-notes><corresp id="cor1"><label>*Corresponding Address:</label><addr-line>P.O. BOX: 1416643931</addr-line><addr-line>Department of Clinical Nutrition</addr-line><addr-line>School of Nutritional Sciences and Dietetics</addr-line><institution>Tehran University of Medical Sciences</institution><addr-line>International Campus</addr-line><addr-line>Tehran</addr-line><country>Iran</country>
Email:<email>mhosseinzadeh@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Winter</season><year>2018</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2017</year></pub-date><volume>19</volume><issue>4</issue><fpage>627</fpage><lpage>633</lpage><history><date date-type="received"><day>29</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><sec><title>Objective</title><p> Polycystic ovary syndrome (PCOS), an ovarian-pituitary axis androgen disorder, is a common endocrine
disease in women. Obesity-induced androgenesis and imbalance of adipokine secretion may lead to some metabolic
features of PCOS. The beneficial effects of polyphenolic compounds such as quercetin have been reported, however,
the underlying molecular mechanism is not entirely understood. In the present study, we investigated the effect of
quercetin supplementation on the expression of adiponectin receptors at the transcript level in peripheral blood
mononuclear cells (PBMC) samples of PCOS patients.
</p></sec><sec><title>Materials and Methods</title><p> In this randomized clinical trial, 84 PCOS subjects were randomly assigned to two groups; the
treatment group received 1 g quercetin (two 500 mg capsules) daily for 12 weeks and the control group received placebo.
To examine the effect of quercetin supplementation on PCOS patients in addition to biochemical and anthropometric
assessments, the expression of <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> at the transcript level and AMPK level were determined by
quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and ELISA assays respectively.
</p></sec><sec><title>Results</title><p> Oral quercetin supplementation significantly increased <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> transcript expression by
1.32- and 1.46-fold respecetively (P&#x0003c;0.01). In addition, quercetin supplementation enhanced AMPK level by 12.3%
compared with the control group (P&#x0003c;0.05).
</p></sec><sec><title>Conclusion</title><p>Oral quercetin supplementation improves the metabolic features of PCOS patients by upregulating the
expression of adiponectin receptors and AMPK (Registration Number: IRCT2013112515536N1).</p></sec></abstract><kwd-group><kwd>Adiponectin Receptors</kwd><kwd>Polycystic Ovary Syndrome</kwd><kwd>Quercetin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Rezvan N, Moini A, Gorgani-Firuzjaee S, Hosseinzadeh-Attar MJ. Oral quercetin supplementation enhances adiponectin receptor transcript
expression in polycystic ovary syndrome patients: a randomized placebo-controlled double-blind clinical trial. Cell J. 2018; 19(4): 627-633. doi: 10.22074/cellj.2018.4577.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Polycystic ovary syndrome (PCOS) is a multifactorial
metabolic disorder with an unknown underlying molecular
mechanism. Hyperinsulinemia, a consequence of insulin
resistance, is a culprit of PCOS pathogenesis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). In
addition, obesity substantially exacerbates this detrimental
condition where reproductive-age obese women with PCOS
are very prone to glucose intolerance (<xref rid="B3" ref-type="bibr">3</xref>). Previous studies
have reported that an excessive visceral fat distribution and an
imbalanced adipokine profile are not only markers of insulin
resistance, but they also can trigger PCOS development via
activation of the pituitary-ovary axis (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Adipokines are
peptide hormones mostly derived from the adipose tissue
(<xref rid="B6" ref-type="bibr">6</xref>). Several peptide hormones and adipokines (such as
adiponectin, omentin and ghrelin) are present abnormally
in women with PCOS (<xref rid="B7" ref-type="bibr">7</xref>). It is thought that leptin and
adiponectin enhance the release of growth hormones (<xref rid="B8" ref-type="bibr">8</xref>), the
follicle stimulating hormone (FSH), the luteinizing hormone
(LH) (<xref rid="B9" ref-type="bibr">9</xref>) and the thyroid stimulating hormone (TSH) by
activating their pituitary receptors (<xref rid="B6" ref-type="bibr">6</xref>). Also, some adipokines
directly affect ovarian steroidogenesis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>) while others (e.g.
adiponectin and omentin) play beneficial roles in glucose
homeostasis by increasing insulin-stimulated glucose uptake
via Akt phosphorylation (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Moreover, they reduce
cardiovascular risk through amelioration of inflammation (<xref rid="B6" ref-type="bibr">6</xref>,
<xref rid="B12" ref-type="bibr">12</xref>). The impaired adiponectin-mediated insulin sensitivity
is observed in obese individuals including PCOS patients
(<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Moreover, previous studies have demonstrated low
levels of adiponectin in PCOS subjects even in the absence of
adiposity (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Adiponectin signaling is controlled by its receptors,
<italic>ADIPOR1</italic> and <italic>ADIPOR2</italic>, which regulate glucose and fatty
acid metabolism partly via the activation of AMP-activated
protein kinase (AMPK) (<xref rid="B2" ref-type="bibr">2</xref>). <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> belong to
the G protein-coupled receptors family. However, in contrast to common G protein-coupled receptors, their N-terminus
is internal while the C-terminus is external (<xref rid="B16" ref-type="bibr">16</xref>). It has been
shown that adiponectin receptors are upregulated at the
transcript and protein levels in adipocytes of PCOS women
but not in their peripheral blood mononuclear cells (PBMC)
(<xref rid="B17" ref-type="bibr">17</xref>). Quercetin (3,3&#x00374;,4&#x00374;,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>- pentahydroxyflavone), a
flavonoid with antioxidant and anti-inflammatory properties,
is found in food such as apples and onions, and drinks such
as tea and red wine (<xref rid="B18" ref-type="bibr">18</xref>). A large body of evidence has
shown its beneficial effects on metabolic disorders such as
obesity, insulin resistance and cardiovascular disease (<xref rid="B19" ref-type="bibr">19</xref>).
Previous studies on animal models have illustrated that
administration of this flavonoid ameliorates dyslipidemia,
hypertension, hyperinsulinemia and tumor necrosis factoralpha
(TNF-&#x003b1;) production (<xref rid="B20" ref-type="bibr">20</xref>). Also, it has been shown
that quercetin supplementation in high fat diet-induced
obese mice resulted in lower levels of glucose, insulin,
triglycerides and cholesterol but increased the secretion of
adiponectin. This finding confirmed the benefecial effects
of quercitin administration on methabolic features of obesity
(<xref rid="B21" ref-type="bibr">21</xref>). Importantly, the bioavailability of oral administration
of quercetin was observed in healthy subjects (<xref rid="B22" ref-type="bibr">22</xref>). In
humans, quercetin induces nitric oxide release and reduces
the production of free radicals, which in turn improve blood
pressure and anti-atherosclerosis capacity (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>).</p><p>To the best of our knowledge, these beneficial effects are
most likely exerted through the adipokine-mediated insulin
signaling pathway (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). However, no study has directly
examined the effect of quercetin supplementation on the
expression of adiponectin receptor genes. We therefore
investigated the effects of quercetin supplementation on
adiponectin receptor expression at the transcript level in
PBMC and potential adiponectin-mediated expression
changes of AMPK in PCOS patients.</p></sec><sec sec-type="materials-methods"><title>Materials and Methods</title><p>This clinical trial was a randomized placebo-controlled
double-blind trial with a superiority single-arm design.
Women with PCOS were randomly divided into two equal
parallel groups, receiving either quercetin supplement or
placebo. The study protocol was approved by the Ethical
Committee of Tehran University of Medical Sciences. This
study was registered in the Iranian Registry of Clinical Trials
(IRCT2013112515536N1). Eighty-four PCOS women
diagnosed according to the 2003 Rotterdam criteria (<xref rid="B27" ref-type="bibr">27</xref>) were
voluntarily recruited at Arash Hospital (Tehran, Iran) from
January 2014 to January 2015. All women were 20-40 years
of age with body mass index (BMI) ranging from 25 to 40
kg/m<sup>2</sup>. Patients with no history of simultaneous endocrine or
metabolic diseases (e.g. hypo- or hyperthyroidism, androgensecreting
tumors, diabetes mellitus, adrenal hyperplasia
and Cushing&#x02019;s syndrome) were enrolled only. Furthermore,
patients who were prescribed with interfering medications
(e.g. metformin and contraceptive, antihypertensive, antiglycemic,
anti-hyperlipidemia or anti-inflammatory drugs)
were excluded. All the recruited patients were informed about
the purpose of the study and completed a written informed
consent. Patients were free to discontinue the trial at any time
during the study.</p><p>This clinical trial consisted of a 12-week treatment with
quercetin or placebo (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). The quercetin group (n=42)
was given one gram daily (Jarrow, USA) in the form of
two 500-mg capsules after each main meal (breakfast
and lunch). Song et al. (<xref rid="B30" ref-type="bibr">30</xref>) have reported that the most
effective dose of quercetin on glycemic status is 60 mg/
kg, approximately equivalent to 4 g for an adult human,
however, importantly, quercetin supplementations have
been shown to be beneficial in humans even with lower
doses (e.g., 500 mg/daily and 1000 mg/daily) (<xref rid="B30" ref-type="bibr">30</xref>-<xref rid="B32" ref-type="bibr">32</xref>). The
Placebo group (n=42) was given two starch-containing
capsules for 12 weeks. Placebo capsules were in the
same shape as quercetin capsules and were produced at
the School of Pharmacy of Tehran University of Medical
Sciences. We monitored the compliance of the volunteers
by counting the returned capsules every two weeks.
Participants were asked to maintain their diet and physical
activity during the study.</p><sec><title>Anthropometric and biochemical analysis</title><p>
Body weight was measured by a scale (Seca, Germany)
with patients wearing no shoes and having light clothing.
Height was measured by a metric mounted tape. BMI was
then calculated as weight over squared height (kg/m<sup>2</sup>). Waist
and hip circumference (WC and HiC) were determined using
a soft metric tape in standing position. It is worth noting that
WC was measured at the narrowest circumference between
the costal margin and the iliac crest, and HiC at the widest
circumference between the waists and tights. Waist to hip
ratio (WHR) was then calculated as WC in centimeters
divided by HiC in centimeters. Systolic and diastolic blood
pressures (SBP and DBP respectively) were checked by a
sphygmomanometer (Rester) in a sitting position after 5-10
minutes rest. Blood samples (12 ml) were collected after 12
hours of fasting between 7 and 9 am. Blood samples were
centrifuged at 4000 rpm for 5 minutes, and sera were then
stored at -80&#x002da;C until further analysis. Biochemical parameters
such as fasting blood sugar and lipid profile [triglycerides
(TG), total cholesterol, high-density lipoproteins-cholesterol
(HDL-C), and low-density lipoproteins- cholesterol (LDL-C)]
were measured by Pars Azmon enzymatic methods and
analyzed on a Hitachi 717 autoanalyser.</p></sec><sec><title>Peripheral blood mononuclear cells isolation</title><p>
PBMC were isolated from 7 ml heparinized whole blood
by using a Ficoll-Hypaque density gradient centrifugation.
The PBMC were washed twice with phosphate-buffered
saline (PBS) and stored at -70&#x002da;C until RNA extraction.</p></sec><sec><title>RNA extraction and first strand cDNA synthesis</title><p>
Total RNA of collected PBMCs was isolated using the total
RNA Extraction RNeasy Mini Kit (Qiagen, Germany). Its
quantity and quality were examined by Nanodrop and agarose
gel electrophoresis respectively. To eliminate the effect of
different number of isolated PBMC from patients, 500 ng of
total RNA was reverse transcribed to cDNA with the M-MuLV
reverse transcriptase and random hexamer primers (miScript
II RT Kit, Qiagen) in 2 steps. Initially, a polyadenylation
reaction was carried out at 37&#x002da;C for 30 minutes and then, the
reverse transcription step was conducted.</p></sec><sec><title>Quantitative real-time polymerase chain reaction</title><p>
Quantitative real time-PCR was performed using the
SYBR Green Premix EX Taq II (Takara Biotechnology,
LTD, Dalian, Japan). Gene expression levels were quantified
using specific primers for <italic>ADIPOR1, ADIPOR2</italic> and <italic>&#x003b2;-actin</italic>
as an internal control (<xref ref-type="table" rid="T1">Table 1</xref>). The levels of target gene
transcripts were normalized relative to those of &#x003b2; actin (delta
CT). The amplification protocol was an initial activation step
for 10 seconds at 95&#x002da;C followed by 40 cycles of 5 seconds at
95&#x002da;C for denaturation and 20 seconds at 60&#x002da;C for annealing/
extension.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Primers sequences used in this study</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="2" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">Primer</th><th rowspan="1" colspan="1">Primer sequencing (5&#x002ca;-3&#x002ca;)</th></tr><tr><th colspan="2" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="2" valign="top" colspan="1"><italic>ADIPOR1</italic></td><td rowspan="1" colspan="1">F: CTTCTACTGCTCCCCACAGC</td></tr><tr><td rowspan="1" colspan="1">R: GACAAAGCCCTCAGCGATAG</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1"><italic>ADIPOR2</italic></td><td rowspan="1" colspan="1">F: CATGTCCCCTCTCTTACAAG</td></tr><tr><td rowspan="1" colspan="1">R: ATGTGTCCAAATGTTGCCTG</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1"><italic>&#x003b2;-actin</italic></td><td rowspan="1" colspan="1">F: ATAGCACAGCCTGGATAGCAACGTAC</td></tr><tr><td rowspan="1" colspan="1">R: CACCTTCTACAATGAGCTGCGTGTG</td></tr><tr><th colspan="2" rowspan="1"><hr/></th></tr></tbody></table></table-wrap></sec><sec><title>Serum p-AMPK measurements</title><p>
Serum p-AMPK levels were measured by human
phosphorylated adenosine monophosphate activated
protein kinase (AMPK) ELISA kit (Bioassay Technology
Laboratory, China).</p></sec><sec><title>Statistical analyses</title><p>
Quantitative variables were presented as mean (&#x000b1; SD or
SE where appropriate). The independent t test was used to
compare the mean of quantitative variables between two
groups. We used the analysis of covariance (ANCOVA)
to compare the mean of post-intervention continuous
outcomes between two groups by adjusting for preintervention
results. Statistical analyses were undertaken
in SPSS 20.0 (IBM SPSS Statistics for Windows, Version
20.0. Armonk, NY: IBM Corp). P&#x0003c;0.05 were considered
statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>General characteristics of the two groups showed
that all anthropometric features were similar in the two
studied groups except for DBP (<xref ref-type="table" rid="T2">Table 2</xref>). The comparison
of crude and adjusted values of post-intervention quercetin
and placebo groups were not significantly different with
respect to BMI, WHR and weight (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>After controlling for relevant confounding factors
including age, DBP and sex hormone binding globulin
LH (SHBG) and considering baseline values of each
variable as covariates, the metabolic profile showed a
significant difference between the two groups. Moreover,
FBS and insulin levels, as well as calculated HOMA-IR
as an index of insulin resistance, were significantly lower
in the quercetin group compared with the placebo group
(<xref ref-type="table" rid="T4">Table 4</xref>).</p><sec><title>Quercetin supplementation induced adiponectin
receptor expression</title><p>
To investigate the molecular mechanism of the effect of
quercetin supplementation on crosstalk between adipose
tissue and reproductive system, we targeted <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> transcript expression in isolated PBMC of
PCOS patients. Quercetin supplementation significantly
upregulated both <italic>ADIPOR1, ADIPOR2</italic> transcript expression
(1.32- and 1.46-fold respectively, P&#x0003c;0.01, <xref ref-type="fig" rid="F1">Fig .1</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical and biochemical characteristics of the study participants in the quercetin and placebo groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">Baseline Characteristic</th><th rowspan="1" colspan="1">Quercetin n=42</th><th rowspan="1" colspan="1">Placebo n=40</th><th rowspan="1" colspan="1">P value<sup>*</sup></th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Age (Y)</td><td rowspan="1" colspan="1">29.45 (4.09)</td><td rowspan="1" colspan="1">30.00 (5.44)</td><td rowspan="1" colspan="1">0.607</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight) kg)</td><td rowspan="1" colspan="1">76.46 (11.89)</td><td rowspan="1" colspan="1">74.89 (11.74)</td><td rowspan="1" colspan="1">0.550</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1"> 29.32 (3.71)</td><td rowspan="1" colspan="1">28.61 (4.06)</td><td rowspan="1" colspan="1">0.411</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR(cm)</td><td rowspan="1" colspan="1">0.83 (0.02)</td><td rowspan="1" colspan="1">0.83 (0.02)</td><td rowspan="1" colspan="1">0.233</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP(mmHg)</td><td rowspan="1" colspan="1">12.63 (0.66)</td><td rowspan="1" colspan="1">12.56 (0.67)</td><td rowspan="1" colspan="1">0.644</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP(mmHg)</td><td rowspan="1" colspan="1">8.79 (0.72)</td><td rowspan="1" colspan="1">8.43 (0.64)</td><td rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">FBS (mg/dL)</td><td rowspan="1" colspan="1">91.57 (6.74)</td><td rowspan="1" colspan="1">89.83 (6.36)</td><td rowspan="1" colspan="1">0.231</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin (&#x003bc;IU/mL)</td><td rowspan="1" colspan="1">10.09 (2.78)</td><td rowspan="1" colspan="1">9.91 (2.56)</td><td rowspan="1" colspan="1">0.754</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td rowspan="1" colspan="1">2.28 (0.72)</td><td rowspan="1" colspan="1">2.20 (0.68)</td><td rowspan="1" colspan="1">0.604</td></tr><tr><td align="left" rowspan="1" colspan="1">SHBG ( nmol/l)</td><td rowspan="1" colspan="1">41.04 (17.73)</td><td rowspan="1" colspan="1">35.62 (13.04)</td><td rowspan="1" colspan="1">0.120</td></tr><tr><td align="left" rowspan="1" colspan="1">LH(mIU/ml)</td><td rowspan="1" colspan="1">8.40 (3.03)</td><td rowspan="1" colspan="1">8.67 (2.07)</td><td rowspan="1" colspan="1">0.644</td></tr><tr><td align="left" rowspan="1" colspan="1">Testosterone</td><td rowspan="1" colspan="1">0.78 (0.16)</td><td rowspan="1" colspan="1">0.78 (0.15)</td><td rowspan="1" colspan="1">0.941</td></tr><tr><td align="left" rowspan="1" colspan="1">Adiponectin (Total) (ng/mL)</td><td rowspan="1" colspan="1">9.58 (1.80)</td><td rowspan="1" colspan="1">10.05 (1.24)</td><td rowspan="1" colspan="1">0.163</td></tr><tr><td align="left" rowspan="1" colspan="1">Adiponectin (HMW) </td><td rowspan="1" colspan="1">5.12 (1.01)</td><td rowspan="1" colspan="1">5.30 (0.91)</td><td rowspan="1" colspan="1">0.421</td></tr><tr><td align="left" colspan="4" rowspan="1">All values are mean (SD). BMI; Body mass index, WHR; Waist to hip ratio, SBP; Systolic blood pressure, DBP; Diastolic blood pressure, FBS; Fasting blood sugar, LH; Luteinizing hormone, SHBG; Sex hormone binding globulin LH, HOMA-IR; Homeostasis model assessment-insulin resistance, HMW; High molecular weight, and *; Significances are based on independent t test.</td></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>All values are mean (SD). BMI; Body mass index, WHR; Waist to hip ratio, SBP; Systolic blood pressure, DBP; Diastolic blood pressure, FBS; Fasting blood
sugar, LH; Luteinizing hormone, SHBG; Sex hormone binding globulin LH, HOMA-IR; Homeostasis model assessment-insulin resistance, HMW; High
molecular weight, and *; Significances are based on independent t test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p> Post-intervention anthropometric characteristics of women with PCOS randomly allocated into the placebo and treatment (quercetin) groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><th rowspan="2" colspan="1">Characteristic</th><th colspan="2" rowspan="1">Quercetin n=42</th><th colspan="2" rowspan="1">Placebo n=40</th><th rowspan="2" colspan="1">Crude P value</th><th rowspan="2" colspan="1">Adjusted P value</th></tr><tr><th rowspan="1" colspan="1">Crude</th><th rowspan="1" colspan="1">Adjusted</th><th rowspan="1" colspan="1">Crude</th><th rowspan="1" colspan="1">Adjusted</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">76.13 (1.85)</td><td rowspan="1" colspan="1">75.40 (0.72)</td><td rowspan="1" colspan="1">74.82 (1.85)</td><td rowspan="1" colspan="1">75.59 (0.70)</td><td rowspan="1" colspan="1">0.618</td><td rowspan="1" colspan="1">0.085</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1">29.19 (0.58)</td><td rowspan="1" colspan="1">28.86 (0.03)</td><td rowspan="1" colspan="1">28.59 (0.64)</td><td rowspan="1" colspan="1">28.93 (0.03)</td><td rowspan="1" colspan="1">0.485</td><td rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR</td><td rowspan="1" colspan="1">0.83 (0.01)</td><td rowspan="1" colspan="1">0.83 (0.00)</td><td rowspan="1" colspan="1">0.83 (0.01)</td><td rowspan="1" colspan="1">0.83 (0.00)</td><td rowspan="1" colspan="1">0.584</td><td rowspan="1" colspan="1">0.107</td></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>All values are mean (SE). Crude comparisons are based on independent t test and adjusted comparisons are based on ANCOVA with variables age, DBP,
SHBG and considering baseline value of each variable as covariates. PCOS; Polycystic ovary syndrome, BMI; Body mass index, WHR; Waist to hip ratio,
DBP; Diastolic blood pressure, and SHBG; Sex hormone binding globulin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p> Post-intervention metabolic profile of women with PCOS randomly allocated into the placebo and treatment (quercetin) groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><th rowspan="2" colspan="1">Characteristic</th><th colspan="2" rowspan="1">Quercetin n=42</th><th colspan="2" rowspan="1">Placebo n=40</th><th rowspan="2" colspan="1">Crude P value</th><th rowspan="2" colspan="1">Adjusted P value</th></tr><tr><th rowspan="1" colspan="1">Crude</th><th rowspan="1" colspan="1">Adjusted</th><th rowspan="1" colspan="1">Crude</th><th rowspan="1" colspan="1">Adjusted</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Insulin (&#x003bc;IU/mL)</td><td rowspan="1" colspan="1">8.45 (0.34)</td><td rowspan="1" colspan="1">8.35 (0.15)</td><td rowspan="1" colspan="1">9.81 (0.41)</td><td rowspan="1" colspan="1">9.91 (0.15)</td><td rowspan="1" colspan="1">0.013<sup>*</sup></td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">FBS (mg/dl)</td><td rowspan="1" colspan="1">90.36 (1.03)</td><td rowspan="1" colspan="1">89.58 (0.23)</td><td rowspan="1" colspan="1">89.45 (0.98)</td><td rowspan="1" colspan="1">90.27 (0.23)</td><td rowspan="1" colspan="1">0.526</td><td rowspan="1" colspan="1">0.045<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td rowspan="1" colspan="1">1.88 (0.09)</td><td rowspan="1" colspan="1">1.84 (0.03)</td><td rowspan="1" colspan="1">2.17 (0.11)</td><td rowspan="1" colspan="1">2.21 (0.04)</td><td rowspan="1" colspan="1">0.039</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>*</sup></td></tr><tr><td align="left" colspan="7" rowspan="1">All values are mean (SE). Crude Significances are based on independent t test and adjusted significances are based on ANCOVA with variables age, BMI, DBP, SHBG and considering baseline value of each variable as covariates. PCOS; Polycystic ovary syndrome, FBS; Fasting blood sugar, HOMA-IR; Homeostasis model assessment-insulin resistance, and <sup>*</sup>; Statistically significant (P&#x0003c;0.05).</td></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>All values are mean (SE). Crude Significances are based on independent t test and adjusted significances are based on ANCOVA with variables age,
BMI, DBP, SHBG and considering baseline value of each variable as covariates. PCOS; Polycystic ovary syndrome, FBS; Fasting blood sugar, HOMA-IR;
Homeostasis model assessment-insulin resistance, and *; Statistically zsignificant (P&#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Fig.1</label><caption><p>Effect of quercetin supplementation on adiponectin receptor transcript expression. A. <italic>ADIPOR1</italic> transcript expression and B. <italic>ADIPOR2</italic> transcript
expression. All 42 samples in each group were run in duplicate. *; P&#x0003c;0.01 and #; P&#x0003e;0.05.</p></caption><graphic xlink:href="Cell-J-19-627-g01"/></fig></sec><sec><title>Quercetin supplementation induced AMPK</title><p>
To further investigate the effect of the adiponectin
receptor signaling pathway, we analyzed the expression
of a downstream molecular target, AMPK. The results
showed that quercetin supplementation enhances the
AMPK level by 12.3% compared with the control group
(P&#x0003c;0.05) (<xref ref-type="fig" rid="F2">Fig .2</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Fig.2</label><caption><p>Effect of quercetin supplementation on serum AMPK level.
*; P&#x0003c;0.01 and #; P&#x0003e;0.05.</p></caption><graphic xlink:href="Cell-J-19-627-g02"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study provides direct evidence for a novel link
between quercetin, a compound of alternative medicine,
and metabolic features of PCOS via adiponectin
receptors and AMPK. We demonstrated that quercetin
supplementation upregulated adiponectin receptors
(<italic>ADIPOR1</italic> and <italic>ADIPOR2</italic>) and AMPK at the transcript and
protein level respectively in PCOS patients. Adiponectin,
the prominent human adipokine, is usually reduced in
obese PCOS subjects (<xref rid="B8" ref-type="bibr">8</xref>). We have previously shown
that quercetin supplementation enhances adiponectin
levels in PCOS women (<xref rid="B33" ref-type="bibr">33</xref>). According to in vitro and
in vivo studies on other polyphenols such as resveratrol
it is established that adiponectin is increased by these
supplements (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>Induction of adiponectin receptors in PBMC of
PCOS women in the presence of quercetin suggests that
quercetin supplementation enhances adiponectin signal
transduction, which is responsible for the beneficial
hypolipidemic effects of quercetin supplementation in
PCOS patients. Consistent with our finding, previous
studies have found that the expression of adiponectin
receptors is elevated in adipose tissue of PCOS women,
thus enhancing adiponectin signaling in adipose tissue
(<xref rid="B17" ref-type="bibr">17</xref>). In addition, Zhang et al. (<xref rid="B35" ref-type="bibr">35</xref>) showed that induction
of <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> in PCOS patients leads to
the early development of the embryo. More importantly,
Tan et al. (<xref rid="B36" ref-type="bibr">36</xref>) demonstrated that elevation of adiponectin
receptors at the transcript level is associated with the
in vivo clearance of triglycerides in postprandial states.
Also, Comim et al. (<xref rid="B37" ref-type="bibr">37</xref>) reported that reduction in serum
adiponectin levels and downregulation of its receptors
causes defects in its signaling. Interestingly, the lower
level of adiponectin and adiponectin receptors in theca
cells significantly contributes to the exacerbation of
hyperandrogenism in overweight or obese women
with PCOS. Furthermore, they demonstrated that other
adipokines, such as leptin and visfatin can slightly
enhance the basal androgen secretion in bovine theca cells
via unknown mechanisms. Leiherer et al. (<xref rid="B38" ref-type="bibr">38</xref>) reported
that quercetin also altered expression of some adipokines
including Angptl4, adipsin, irisin and PAI-1 in addition
to glucose catabolism genes, ENO2, PFKP and PFKFB4.
They suggested that quercetin supplementation exerts
its beneficial effects not only by its antioxidant capacity
but also by targeting metabolic pathways and adipokine
expression.</p><p>Altogether, reduction of adiponectin and its receptors is
a key mechanism which links metabolic and reproductive
dysfunctions in women with PCOS (<xref rid="B37" ref-type="bibr">37</xref>). Our study
suggests that amelioration of the adiponectin signaling by
augmenting the expression of its receptors after quercetin
supplementation improves the metabolic features of
PCOS. Importantly, it has been shown that quercetin
supplementation in an animal model reduced insulin
resistance and improved therapeutic effects in PCOS rats.
Also, it was demonstrated that mechanistically quercetin
inhibits the Toll-like receptor/NF-&#x003ba;B signaling pathway
and in turn enhances the inflammatory microenvironment
of the ovarian tissue of the PCOS rat model (<xref rid="B39" ref-type="bibr">39</xref>). Further
evidence supports the anti-hypertensive and antiatherosclerotic
advantages of quercitin supplementation
in reducing atherosclerosis (<xref rid="B24" ref-type="bibr">24</xref>). Notably, quercetin
supplementation improves dyslipidemia, hypertension
and hyperinsulinemia as well as weight loss in diabetic
mice, by reducing TNF-&#x003b1; production (<xref rid="B40" ref-type="bibr">40</xref>). Quercetin
supplementation in animal models reduced glucose,
insulin, triglyceride and cholesterol levels, however, it
enhanced serum adiponectin levels (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Wein et al.
(<xref rid="B25" ref-type="bibr">25</xref>) reported that the effect of quercetin in high fat-fed rats
is due to the direct action of quercetin and independent of
body stored fat size, improves insulin sensitivity and the
HOMA index.</p><p>In parallel to the elevated expression of adiponectin
receptors at the transcript level, quercetin also significantly
enhanced the AMPK level. In this context, the positive
correlation of <italic>ADIPOR1</italic> and <italic>ADIPOR2</italic> and serum AMPK
overexpression suggests that quercetin supplementation
exerts its beneficial metabolic effects in PCOS patients
by targeting adiponectin and AMPK signaling pathways.
While these three molecules are expressed in the ovary,
it is reasonable to examine the biological actions of fuel
sensors in fertility and it importance in fertility problems
(<xref rid="B2" ref-type="bibr">2</xref>). We conclude that due to the detrimental inflammatory
and metabolic characteristics of PCOS, quercetin, an antiinflammatory
molecule, may mechanistically improve the
metabolic features of PCOS by upregulating AMPK and
adiponectin receptors. It would be worthy to confirm this
finding by conducting in vitro studies on appropriate cell
lines.</p></sec></body><back><ack><p>This research was financially supported by the
International Campus, Tehran University of Medical
Sciences (TUMS. IC) (grant number: 104428). Also, we
would like to thank the staff of the Obstetrics Clinic of the
Arash Hospital, Tehran University of Medical Sciences,
Tehran, Iran for their assistance. There is no conflict of
interest in this study.</p></ack><bio id="d35e942"><title>Author&#x02019;s Contributions</title><p>N.R., S.GF.; Researched data and wrote the manuscript.
A.M.; Contributed in sample preparation. M.J.H.;
Reviewed, edited the manuscript, supervised team. All
authors read and approved the final manuscript.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlik</surname><given-names>B</given-names></name><name><surname>Madej</surname><given-names>P</given-names></name><name><surname>Owczarek</surname><given-names>A</given-names></name><name><surname>Ska&#x00142;ba</surname><given-names>P</given-names></name><name><surname>Chudek</surname><given-names>J</given-names></name><name><surname>Olszanecka- Glinianowicz</surname><given-names>M</given-names></name></person-group><article-title>Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome</article-title><source>Clin Endocrinol (Oxf)</source><year>2014</year><volume>81</volume><issue>4</issue><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">24392647</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name></person-group><article-title>Adiponectin receptor signaling: a new layer to the current model</article-title><source>Cell Metab</source><year>2011</year><volume>13</volume><issue>2</issue><fpage>123</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">21284979</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>TM</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Wass</surname><given-names>JA</given-names></name><name><surname>Franks</surname><given-names>S</given-names></name></person-group><article-title>Obesity and polycystic ovary syndrome</article-title><source>Clin Endocrinol (Oxf)</source><year>2006</year><volume>65</volume><issue>2</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">16886951</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olszanecka-Glinianowicz</surname><given-names>M</given-names></name><name><surname>Madej</surname><given-names>P</given-names></name><name><surname>Nylec</surname><given-names>M</given-names></name><name><surname>Owczarek</surname><given-names>A</given-names></name><name><surname>Szanecki</surname><given-names>W</given-names></name><name><surname>Ska&#x00142;ba</surname><given-names>P</given-names></name><etal/></person-group><article-title>Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances</article-title><source>Clin Endocrinol (Oxf)</source><year>2013</year><volume>79</volume><issue>2</issue><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">23199261</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olszanecka-Glinianowicz</surname><given-names>M</given-names></name><name><surname>Madej</surname><given-names>P</given-names></name><name><surname>Zdun</surname><given-names>D</given-names></name><name><surname>Bo&#x0017c;entowicz- Wikarek</surname><given-names>M</given-names></name><name><surname>Sikora</surname><given-names>J</given-names></name><name><surname>Chudek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2012</year><volume>162</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22397743</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psilopanagioti</surname><given-names>A</given-names></name><name><surname>Papadaki</surname><given-names>H</given-names></name><name><surname>Kranioti</surname><given-names>EF</given-names></name><name><surname>Alexandrides</surname><given-names>TK</given-names></name><name><surname>Varakis</surname><given-names>JN</given-names></name></person-group><article-title>Expression of adiponectin and adiponectin receptors in human pituitary gland and brain</article-title><source>Neuroendocrinology</source><year>2009</year><volume>89</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18698133</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reaux-Le Goazigo</surname><given-names>A</given-names></name><name><surname>Alvear-Perez</surname><given-names>R</given-names></name><name><surname>Zizzari</surname><given-names>P</given-names></name><name><surname>Epelbaum</surname><given-names>J</given-names></name><name><surname>Bluet-Pajot</surname><given-names>MT</given-names></name><name><surname>Llorens-Cortes</surname><given-names>C</given-names></name></person-group><article-title>Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release</article-title><source>Am J Physiol Endocrinol Metab</source><year>2007</year><volume>292</volume><issue>1</issue><fpage>E7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16896162</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tersigni</surname><given-names>C</given-names></name><name><surname>Di Nicuolo</surname><given-names>F</given-names></name><name><surname>D&#x02019;Ippolito</surname><given-names>S</given-names></name><name><surname>Veglia</surname><given-names>M</given-names></name><name><surname>Castellucci</surname><given-names>M</given-names></name><name><surname>Di Simone</surname><given-names>N</given-names></name></person-group><article-title>Adipokines: new emerging roles in fertility and reproduction</article-title><source>Obstet Gynecol Surv</source><year>2011</year><volume>66</volume><issue>1</issue><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21510912</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Pessin</surname><given-names>JE</given-names></name></person-group><article-title>Adipokines mediate inflammation and insulin resistance</article-title><source>Front Endocrinol (Lausanne)</source><year>2013</year><volume>4</volume><fpage>71</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">23781214</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name></person-group><article-title>Adiponectin and adiponectin receptors</article-title><source>Endocr Rev</source><year>2005</year><volume>26</volume><issue>3</issue><fpage>439</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">15897298</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>RZ</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Pray</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>HB</given-names></name><name><surname>Hansen</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action</article-title><source>Am J Physiol Endocrinol Metab</source><year>2006</year><volume>290</volume><issue>6</issue><fpage>E1253</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">16531507</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamawaki</surname><given-names>H</given-names></name><name><surname>Kuramoto</surname><given-names>J</given-names></name><name><surname>Kameshima</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name></person-group><article-title>Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells</article-title><source>Biochem Biophys Res Commun</source><year>2011</year><volume>408</volume><issue>2</issue><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">21514279</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group><article-title>Adipose tissue: from lipid storage compartment to endocrine organ</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><issue>6</issue><fpage>1537</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">16731815</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>BK</given-names></name><name><surname>Adya</surname><given-names>R</given-names></name><name><surname>Farhatullah</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lehnert</surname><given-names>H</given-names></name><name><surname>Randeva</surname><given-names>HS</given-names></name></person-group><article-title>Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><issue>12</issue><fpage>3023</fpage><lpage>3031</lpage><pub-id pub-id-type="pmid">20852028</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>SW</given-names></name></person-group><article-title>Adiponectin and polycystic ovary syndrome</article-title><source>Biol Res Nurs</source><year>2010</year><volume>12</volume><issue>1</issue><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20498127</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Tsuchida</surname><given-names>A</given-names></name><name><surname>Yokomizo</surname><given-names>T</given-names></name><name><surname>Kita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cloning of adiponectin receptors that mediate antidiabetic metabolic effects</article-title><source>Nature</source><year>2003</year><volume>423</volume><issue>6941</issue><fpage>762</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">12802337</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Digby</surname><given-names>J</given-names></name><name><surname>Keay</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Randeva</surname><given-names>HS</given-names></name></person-group><article-title>Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><issue>11</issue><fpage>2723</fpage><lpage>2728</lpage><pub-id pub-id-type="pmid">17001470</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>DO</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name></person-group><article-title>Major phenolics in apple and their contribution to the total antioxidant capacity</article-title><source>J Agric Food Chem</source><year>2003</year><volume>51</volume><issue>22</issue><fpage>6516</fpage><lpage>6520</lpage><pub-id pub-id-type="pmid">14558772</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname><given-names>A</given-names></name><name><surname>Chuang</surname><given-names>C</given-names></name><name><surname>McIntosh</surname><given-names>M</given-names></name></person-group><article-title>Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media</article-title><source>Int J Obes (Lond)</source><year>2011</year><volume>35</volume><issue>9</issue><fpage>1165</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">21224828</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>MF</given-names></name><name><surname>Hassan</surname><given-names>NA</given-names></name><name><surname>El Bassossy</surname><given-names>HM</given-names></name><name><surname>Fahmy</surname><given-names>A</given-names></name></person-group><article-title>Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e63784</fpage><lpage>e63784</lpage><pub-id pub-id-type="pmid">23717483</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>LK</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ribnicky</surname><given-names>D</given-names></name><name><surname>Soileau</surname><given-names>JL</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Gettys</surname><given-names>TW</given-names></name></person-group><article-title>Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><issue>3</issue><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">19142628</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egert</surname><given-names>S</given-names></name><name><surname>Wolffram</surname><given-names>S</given-names></name><name><surname>Bosy-Westphal</surname><given-names>A</given-names></name><name><surname>Boesch-Saadatmandi</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>AE</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name><etal/></person-group><article-title>Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans</article-title><source>J Nutr</source><year>2008</year><volume>138</volume><issue>9</issue><fpage>1615</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">18716159</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RL</given-names></name><name><surname>Lyon</surname><given-names>T</given-names></name><name><surname>Litwin</surname><given-names>SE</given-names></name><name><surname>Rabovsky</surname><given-names>A</given-names></name><name><surname>Symons</surname><given-names>JD</given-names></name><name><surname>Jalili</surname><given-names>T</given-names></name></person-group><article-title>Quercetin reduces blood pressure in hypertensive subjects</article-title><source>J Nutr</source><year>2007</year><volume>137</volume><issue>11</issue><fpage>2405</fpage><lpage>2411</lpage><pub-id pub-id-type="pmid">17951477</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>T</given-names></name><name><surname>Hanssen</surname><given-names>H</given-names></name><name><surname>Sisic</surname><given-names>Z</given-names></name><name><surname>Pfeiler</surname><given-names>S</given-names></name><name><surname>Summo</surname><given-names>C</given-names></name><name><surname>Schmauss</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immunoregulatory effects of the flavonol quercetin in vitro and in vivo</article-title><source>Eur J Nutr</source><year>2011</year><volume>50</volume><issue>3</issue><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">20652710</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wein</surname><given-names>S</given-names></name><name><surname>Behm</surname><given-names>N</given-names></name><name><surname>Petersen</surname><given-names>RK</given-names></name><name><surname>Kristiansen</surname><given-names>K</given-names></name><name><surname>Wolffram</surname><given-names>S</given-names></name></person-group><article-title>Quercetin enhances adiponectin secretion by a PPAR-gamma independent mechanism</article-title><source>Eur J Pharm Sci</source><year>2010</year><volume>41</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20580672</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>OY</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Do</surname><given-names>H</given-names></name><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Cha</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Influence of Quercetin-rich onion peel extracts on adipokine expression in the visceral adipose tissue of rats</article-title><source>Phytother Res</source><year>2012</year><volume>26</volume><issue>3</issue><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">21833991</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><collab>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group</collab><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">14688154</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Nieman</surname><given-names>DC</given-names></name><name><surname>Shanely</surname><given-names>RA</given-names></name><name><surname>Knab</surname><given-names>AM</given-names></name><name><surname>Austin</surname><given-names>MD</given-names></name><name><surname>Sha</surname><given-names>W</given-names></name></person-group><article-title>The variable plasma quercetin response to 12-week quercetin supplementation in humans</article-title><source>Eur J Clin Nutr</source><year>2010</year><volume>64</volume><issue>7</issue><fpage>692</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">20517329</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knab</surname><given-names>AM</given-names></name><name><surname>Shanely</surname><given-names>RA</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Austin</surname><given-names>MD</given-names></name><name><surname>Sha</surname><given-names>W</given-names></name><name><surname>Nieman</surname><given-names>DC</given-names></name></person-group><article-title>Quercetin with vitamin C and niacin does not affect body mass or composition</article-title><source>Appl Physiol Nutr Metab</source><year>2011</year><volume>36</volume><issue>3</issue><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">21574787</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Kwon</surname><given-names>O</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Daruwala</surname><given-names>R</given-names></name><name><surname>Eck</surname><given-names>P</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and glucose</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>18</issue><fpage>15252</fpage><lpage>15260</lpage><pub-id pub-id-type="pmid">11834736</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazloom</surname><given-names>Z</given-names></name><name><surname>Abdollahzadeh</surname><given-names>SM</given-names></name><name><surname>Dabbaghmanesh</surname><given-names>MH</given-names></name><name><surname>Rezaianzadeh</surname><given-names>A</given-names></name></person-group><article-title>The effect of quercetin supplementation on oxidative stress, glycemic control, lipid profile and insulin resistance in type 2 diabetes: a randomized clinical trial</article-title><source>J Health Sci Surveill Syst</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahedi</surname><given-names>M</given-names></name><name><surname>Ghiasvand</surname><given-names>R</given-names></name><name><surname>Feizi</surname><given-names>A</given-names></name><name><surname>Asgari</surname><given-names>G</given-names></name><name><surname>Darvishi</surname><given-names>L</given-names></name></person-group><article-title>Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial</article-title><source>Int J Prev Med</source><year>2013</year><volume>4</volume><issue>7</issue><fpage>777</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">24049596</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezvan</surname><given-names>N</given-names></name><name><surname>Moini</surname><given-names>A</given-names></name><name><surname>Janani</surname><given-names>L</given-names></name><name><surname>Mohammad</surname><given-names>K</given-names></name><name><surname>Saedisomeolia</surname><given-names>A</given-names></name><name><surname>Nourbakhsh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of quercetin on adiponectin-mediated insulin sensitivity in polycystic ovary syndrome: a randomized placebo-controlled double-blind clinical trial</article-title><source>Horm Metab Res</source><year>2017</year><volume>49</volume><issue>2</issue><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">27824398</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benrick</surname><given-names>A</given-names></name><name><surname>Maliqueo</surname><given-names>M</given-names></name><name><surname>Miao</surname><given-names>S</given-names></name><name><surname>Villanueva</surname><given-names>JA</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Ohlsson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>964070</fpage><lpage>964070</lpage><pub-id pub-id-type="pmid">23690868</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Hao</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhuang</surname><given-names>L</given-names></name><etal/></person-group><article-title>A potential determinant role of adiponectin and receptors for the early embryo development in PCOS patients with obesity hinted by quantitative profiling</article-title><source>Gynecol Endocrinol</source><year>2017</year><volume>33</volume><issue>2</issue><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">27597432</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>GD</given-names></name><name><surname>Debard</surname><given-names>C</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Humphreys</surname><given-names>SM</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Frayn</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><issue>8</issue><fpage>1585</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">15991021</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comim</surname><given-names>FV</given-names></name><name><surname>Hardy</surname><given-names>K</given-names></name><name><surname>Franks</surname><given-names>S</given-names></name></person-group><article-title>Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e80416</fpage><lpage>e80416</lpage><pub-id pub-id-type="pmid">24260388</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiherer</surname><given-names>A</given-names></name><name><surname>Stoemmer</surname><given-names>K</given-names></name><name><surname>Muendlein</surname><given-names>A</given-names></name><name><surname>Saely</surname><given-names>CH</given-names></name><name><surname>Kinz</surname><given-names>E</given-names></name><name><surname>Brandtner</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Quercetin impacts expression of metabolism-and obesity-associated genes in SGBS adipocytes</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><issue>5</issue><!--<pub-id pub-id-type="pii">pii: E282</pub-id>--></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhai</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Quercetin decreases insulin resistance in a polycystic ovary syndrome rat model by improving inflammatory microenvironment</article-title><source>Reprod Sci</source><year>2016</year><!--<pub-id pub-id-type="pii">pii: 1933719116667218</pub-id>--></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>L</given-names></name><name><surname>Mor&#x000f3;n</surname><given-names>R</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>M</given-names></name><name><surname>Zarzuelo</surname><given-names>A</given-names></name><name><surname>Galisteo</surname><given-names>M</given-names></name></person-group><article-title>Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>16</volume><issue>9</issue><fpage>2081</fpage><lpage>2087</lpage><pub-id pub-id-type="pmid">18551111</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobori</surname><given-names>M</given-names></name><name><surname>Masumoto</surname><given-names>S</given-names></name><name><surname>Akimoto</surname><given-names>Y</given-names></name><name><surname>Oike</surname><given-names>H</given-names></name></person-group><article-title>Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice</article-title><source>Mol Nutr Food Res</source><year>2011</year><volume>55</volume><issue>4</issue><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">21462320</pub-id></element-citation></ref></ref-list></back></article>